S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

MEDNAX Stock Forecast, Price & News

+0.30 (+1.13%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
275,418 shs
Average Volume
679,356 shs
Market Capitalization
$2.33 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDNAX and its competitors with MarketBeat's FREE daily newsletter.



MEDNAX, Inc. provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The firm's solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting. The company was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.


See More Headlines

Industry, Sector and Symbol

Health Care Services
Year Founded

Sales & Book Value

Annual Sales
$1.73 billion
Cash Flow
$1.21 per share
Book Value
$9.78 per share


Net Income
$-796.49 million
Pretax Margin




Free Float
Market Cap
$2.33 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

1.78 out of 5 stars

Medical Sector

864th out of 1,394 stocks

Hospitals Industry

7th out of 8 stocks

Analyst Opinion: 1.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

MEDNAX (NYSE:MD) Frequently Asked Questions

Is MEDNAX a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEDNAX stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MD, but not buy additional shares or sell existing shares.
View analyst ratings for MEDNAX
or view top-rated stocks.

How has MEDNAX's stock price been impacted by COVID-19?

MEDNAX's stock was trading at $13.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MD stock has increased by 92.6% and is now trading at $26.94.
View which stocks have been most impacted by COVID-19

When is MEDNAX's next earnings date?

MEDNAX is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for MEDNAX

How were MEDNAX's earnings last quarter?

MEDNAX, Inc. (NYSE:MD) issued its earnings results on Thursday, October, 28th. The company reported $0.46 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.41 by $0.05. The firm earned $493 million during the quarter, compared to the consensus estimate of $480.04 million. MEDNAX had a net margin of 1.05% and a trailing twelve-month return on equity of 12.99%. The business's revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 EPS.
View MEDNAX's earnings history

What price target have analysts set for MD?

8 analysts have issued 1 year target prices for MEDNAX's shares. Their forecasts range from $22.00 to $32.00. On average, they anticipate MEDNAX's stock price to reach $27.88 in the next year. This suggests a possible upside of 3.5% from the stock's current price.
View analysts' price targets for MEDNAX
or view top-rated stocks among Wall Street analysts.

Who are MEDNAX's key executives?

MEDNAX's management team includes the following people:
  • Mark S. Ordan, Chief Executive Officer & Director
  • Roger Mack Hinson, President
  • C. Mark Richards, Chief Financial Officer & Executive Vice President
  • Dominic J. Andreano, Secretary, Executive VP & General Counsel
  • Nikos Nikolopoulos, Chief Strategy & Growth Officer, Executive VP

What is Mark S. Ordan's approval rating as MEDNAX's CEO?

6 employees have rated MEDNAX CEO Mark S. Ordan on Glassdoor.com. Mark S. Ordan has an approval rating of 34% among MEDNAX's employees. This puts Mark S. Ordan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of MEDNAX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include NVIDIA (NVDA), AbbVie (ABBV), QUALCOMM (QCOM), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T), Walt Disney (DIS), Wells Fargo & Company (WFC), Exxon Mobil (XOM) and Advanced Micro Devices (AMD).

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

Who are MEDNAX's major shareholders?

MEDNAX's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.60%), Alliancebernstein L.P. (7.61%), Starboard Value LP (6.84%), Dimensional Fund Advisors LP (4.36%), ArrowMark Colorado Holdings LLC (3.10%) and New York State Common Retirement Fund (1.90%). Company insiders that own MEDNAX stock include John C Pepia, Mark S Ordan, Nicholas J Nikolopoulos, Roger Mack Hinson and Roger Md Medel.
View institutional ownership trends for MEDNAX

Which institutional investors are selling MEDNAX stock?

MD stock was sold by a variety of institutional investors in the last quarter, including Starboard Value LP, BlackRock Inc., River Road Asset Management LLC, Invesco Ltd., Arrowstreet Capital Limited Partnership, Alliancebernstein L.P., Citigroup Inc., and ArrowMark Colorado Holdings LLC. Company insiders that have sold MEDNAX company stock in the last year include John C Pepia, Mark S Ordan, Roger Mack Hinson, and Roger Md Medel.
View insider buying and selling activity for MEDNAX
or view top insider-selling stocks.

Which institutional investors are buying MEDNAX stock?

MD stock was acquired by a variety of institutional investors in the last quarter, including Caas Capital Management LP, Allianz Asset Management GmbH, Morgan Stanley, Nordea Investment Management AB, Millennium Management LLC, New York State Common Retirement Fund, Cornercap Investment Counsel Inc., and Cubist Systematic Strategies LLC.
View insider buying and selling activity for MEDNAX
or or view top insider-buying stocks.

How do I buy shares of MEDNAX?

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEDNAX's stock price today?

One share of MD stock can currently be purchased for approximately $26.94.

How much money does MEDNAX make?

MEDNAX has a market capitalization of $2.33 billion and generates $1.73 billion in revenue each year. The company earns $-796.49 million in net income (profit) each year or $0.22 on an earnings per share basis.

How many employees does MEDNAX have?

MEDNAX employs 5,600 workers across the globe.

When was MEDNAX founded?

MEDNAX was founded in 1979.

What is MEDNAX's official website?

The official website for MEDNAX is www.mednax.com.

Where are MEDNAX's headquarters?

MEDNAX is headquartered at 1301 CONCORD TERRACE, SUNRISE FL, 33323.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at (954) 384-0175, via email at [email protected], or via fax at 954-838-9961.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.